Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB1 | P20618 | 4/20 | 0.66 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.66 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.66 |
| ▸ | LTA4H | P09960 | 13/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23742244 | 0.98 | PSMB1 (0.69) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL21102893 | 0.89 | LTA4H (0.64) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL113405 | 0.86 | LTA4H (0.63) | LTA4HKDM4EHRH3 | |
| SCHEMBL4167205 | 0.84 | PSMB1 (0.60) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL11876046 | 0.83 | LTA4H (0.71) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL11880228 | 0.81 | KDM4E (0.70) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL11881017 | 0.81 | LTA4H (0.69) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL8337754 | 0.81 | HRH3 (0.70) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL19145673 | 0.81 | LTA4H (0.59) | PSMB1PSMB5PSMB2LTA4HKDM4E | |
| SCHEMBL11877770 | 0.81 | HRH3 (0.83) | PSMB1PSMB5LTA4HHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021156636-A1 | TRIAZOLE DERIVATIVES WITH ANTIFUNGAL ACTIVITY | KING'S COLLEGE LONDON (GB) | 2021-08-12 | — | — | WO | disclosed |
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-18 | — | — | US | disclosed |
| US-6133262-A | 3-AMINOBENZO(B)THIOPHENE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0997460-A1 | Benzothiophene compounds as antithrombotic agents and intermediates | ELI LILLY AND COMPANY (US) | 2000-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201608-A1 | SUBSTITUTED NAPHTHYRIDINES AND USE THEREOF AS MEDICINES | NR4A1, NR4A3, NR0B1 | PSMB1 3159/4885PSMB5 1858/4885PSMB2 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.